Our results suggest that the use of inhibitors of the Bcl-2 family of anti-apoptotic proteins may be an effective strategy to sensitize AML cells to drug treatment in patients with extremely high white blood cell counts in the bone marrow. The gene discussed is BCL2; the disease is acute myeloid leukemia.